Mechanisms, reported research dosage ranges, stability behaviour and storage requirements for the compounds most commonly listed by the suppliers in this directory. Dosage figures are summaries of published literature and widely circulated research protocols — they are not instructions.
BPC-157
Body Protection Compound-157
Pentadecapeptide · gastric-derived
Target mechanism
Upregulates VEGFR2 signalling and nitric-oxide pathways, associated in animal models with angiogenesis and accelerated soft-tissue repair of tendon, ligament and gut lining.
Reported research dosage
Literature and community protocols commonly cite 200–500 mcg per administration, once or twice daily, in cycles of 4–8 weeks.
Stability
Comparatively robust for a peptide; tolerates brief room-temperature excursions during shipping better than most. Half-life: short — minutes to a few hours in circulation.
Storage
Lyophilised: freezer, long-term. Reconstituted: 2–8 °C, use within ~4 weeks, protect from light.
Field note · Human clinical evidence remains limited. Most citations are rodent studies. Often sold as an arginate salt, which is more stable in solution than the acetate form.
TB-500
Thymosin Beta-4 fragment
Synthetic peptide fragment
Target mechanism
Binds G-actin and promotes actin sequestration, implicated in cell migration, endothelial differentiation and wound-site repair.
Reported research dosage
Reported research use is typically 2–2.5 mg twice weekly in a 4–6 week loading phase, then a reduced maintenance frequency.
Stability
Stable as a powder; solution stability is average. Avoid repeated freeze–thaw of reconstituted material. Half-life: long relative to bpc-157 — allows infrequent administration.
Storage
Lyophilised: −20 °C. Reconstituted: refrigerated, ~3–4 weeks.
Field note · Frequently paired with BPC-157 in community protocols. On WADA's prohibited list for competitive athletes.
Clinical titration schedules start at 0.25 mg weekly and escalate over months. Rapid escalation is the single most common cause of adverse gastrointestinal effects.
Stability
Sensitive to heat and agitation. Cold-chain shipping matters; vials that arrive warm should be questioned. Half-life: ≈7 days — weekly administration.
Storage
Lyophilised: refrigerated or frozen. Reconstituted: 2–8 °C, never frozen, discard if cloudy.
Field note · Approved pharmaceutical versions exist. Research-grade vials are not equivalent to a prescription product and carry no dosing assurance — under-dosed batches are a documented problem in this category.
Tirzepatide
GIP / GLP-1 dual agonist
Dual incretin agonist
Target mechanism
Activates both GIP and GLP-1 receptors, producing greater effects on glycaemic control and appetite in trials than GLP-1 agonism alone.
Reported research dosage
Clinical schedules begin at 2.5 mg weekly with escalation at 4-week intervals. Research vials are commonly supplied at 10–60 mg total.
Stability
Similar profile to semaglutide: heat- and shear-sensitive, degrades with shaking. Half-life: ≈5 days — weekly administration.
Storage
Lyophilised: refrigerated/frozen. Reconstituted: 2–8 °C, upright, protect from light.
Field note · The highest-value target for counterfeiting and dilution in the grey market. Independent batch assay is strongly advised before any use.
CJC-1295
Modified GRF (1-29), with or without DAC
Growth hormone releasing hormone analogue
Target mechanism
GHRH analogue that increases the amplitude of endogenous growth hormone pulses. The DAC variant binds albumin, extending duration substantially.
Reported research dosage
No-DAC research protocols cite ~100 mcg per administration, 1–3 times daily; DAC versions are cited at ~1–2 mg weekly.
Stability
Good as powder; moderate in solution. Half-life: no-dac: ~30 minutes · with dac: ~6–8 days.
Storage
Lyophilised: freezer. Reconstituted: 2–8 °C, ~3–4 weeks.
Field note · Commonly combined with a ghrelin mimetic such as Ipamorelin for a synergistic pulse. Confirm which variant you have — DAC and no-DAC are not interchangeable at the same dose.
Ipamorelin
Selective ghrelin receptor agonist
Growth hormone secretagogue
Target mechanism
Selective GHSR-1a agonist that stimulates GH release with minimal impact on cortisol, prolactin or ACTH — the reason it is preferred over older secretagogues.
Reported research dosage
Commonly cited at 100–300 mcg per administration, up to three times daily.
Stability
Stable powder; standard solution handling. Half-life: ≈2 hours.
Field note · Considered the mildest of the secretagogues. Frequently stacked with CJC-1295 no-DAC in reported protocols.
GHK-Cu
Copper tripeptide-1
Copper-binding tripeptide
Target mechanism
Copper complex studied for collagen and elastin synthesis, antioxidant signalling and wound remodelling. Used both topically and, in research contexts, subcutaneously.
Reported research dosage
Topical formulations typically sit at 1–3 mg/mL. Reported subcutaneous research use is far lower, commonly 1–2 mg per administration.
Stability
Distinctive deep blue solution — colour is expected, not contamination. Discolouration toward green or brown suggests degradation. Half-life: short in circulation.
Storage
Lyophilised: cool and dark. Reconstituted: 2–8 °C, protect from light; copper complexes are photosensitive.
Field note · Copper load matters with repeated administration. Topical use has the strongest supporting literature.
Retatrutide
LY3437943 · GIP / GLP-1 / glucagon triple agonist
Triple incretin agonist
Target mechanism
Agonist at GIP, GLP-1 and glucagon receptors. The glucagon arm adds an energy-expenditure component on top of the appetite and glycaemic effects of dual agonism.
Reported research dosage
Phase 2 trials titrated from 1 mg weekly upward over months. Research vials are commonly supplied at 5–20 mg total.
Stability
Heat- and agitation-sensitive, same handling class as tirzepatide. Half-life: ≈6 days — weekly administration.
Storage
Lyophilised: refrigerated/frozen. Reconstituted: 2–8 °C, never frozen.
Field note · Still investigational — no approved product exists anywhere. That means every vial on the market is unregulated by definition, and identity assay is essential.
Cagrilintide
Long-acting amylin analogue
Amylin receptor agonist
Target mechanism
Amylin analogue acting on satiety pathways in the hindbrain, slowing gastric emptying and reducing food intake independently of GLP-1 signalling.
Reported research dosage
Trial schedules escalate from 0.25 mg weekly toward 2.4 mg. Frequently paired with semaglutide ('CagriSema') in reported protocols.
Stability
Solution-stable when refrigerated; sensitive to shaking. Half-life: ≈7–8 days.
Storage
Lyophilised: freezer. Reconstituted: 2–8 °C, ~4 weeks.
Field note · Sold widely as a research compound before any approval. Combination use compounds gastrointestinal effects considerably.
Tesamorelin
Egrifta · stabilised GHRH(1-44)
Growth hormone releasing hormone analogue
Target mechanism
GHRH analogue stimulating endogenous GH release; clinically studied for reduction of visceral adipose tissue.
Reported research dosage
Clinically 1–2 mg daily by subcutaneous injection.
Stability
Degrades quickly in solution relative to other GHRH analogues. Half-life: ≈25–40 minutes.
Storage
Lyophilised: refrigerated. Reconstituted: use promptly, 2–8 °C.
Field note · One of the few compounds in this category with an approved pharmaceutical form, which makes the research-grade versions easy to compare against a known standard.
Sermorelin
GRF (1-29)
Growth hormone releasing hormone analogue
Target mechanism
Shortest active GHRH fragment; produces a brief physiological GH pulse that remains subject to somatostatin feedback.
Reported research dosage
Commonly cited at 100–300 mcg before sleep.
Stability
Poor in solution — among the least stable peptides in common circulation. Half-life: ≈10–20 minutes.
Storage
Lyophilised: freezer. Reconstituted: 2–8 °C, ~2 weeks.
Field note · Often the cheapest secretagogue on a supplier's list. Low potency per milligram means underdosing is harder to notice.
Hexarelin
Hexapeptide GH secretagogue
Growth hormone secretagogue
Target mechanism
Potent GHSR agonist. Stronger GH release than ipamorelin but with meaningful cortisol and prolactin elevation.
Reported research dosage
Reported at 100 mcg, one to three times daily, in short cycles.
Stability
Stable powder; standard solution handling. Half-life: ≈55 minutes.
Field note · Receptor desensitisation develops quickly — reported protocols keep cycles short for that reason.
GHRP-2
Pralmorelin
Growth hormone secretagogue
Target mechanism
Ghrelin mimetic driving GH release with a moderate rise in cortisol and prolactin.
Reported research dosage
Commonly cited at 100–300 mcg, up to three times daily.
Stability
Good as powder, average in solution. Half-life: ≈30 minutes.
Storage
Lyophilised: freezer. Reconstituted: 2–8 °C, ~4 weeks.
Field note · Less appetite stimulation than GHRP-6; often paired with a GHRH analogue.
GHRP-6
Growth hormone releasing hexapeptide
Growth hormone secretagogue
Target mechanism
Ghrelin mimetic with pronounced appetite stimulation alongside GH release.
Reported research dosage
Commonly cited at 100–300 mcg, up to three times daily.
Stability
Good as powder, average in solution. Half-life: ≈15–60 minutes.
Storage
Lyophilised: freezer. Reconstituted: 2–8 °C, ~4 weeks.
Field note · Hunger onset within ~20 minutes is the characteristic reported effect.
MK-677
Ibutamoren
Oral growth hormone secretagogue (non-peptide)
Target mechanism
Orally bioavailable GHSR agonist raising GH and IGF-1 continuously rather than in pulses.
Reported research dosage
Commonly cited at 10–25 mg once daily, oral.
Stability
Small molecule — stable at room temperature, no reconstitution required. Half-life: ≈24 hours.
Storage
Cool, dry, dark. No cold chain needed.
Field note · Not a peptide, but sold across the same supplier base. Water retention, appetite increase and reduced insulin sensitivity are the commonly reported effects.
Semax
ACTH(4-10) analogue
Nootropic peptide
Target mechanism
Modulates BDNF and dopaminergic signalling; studied in Russia for stroke recovery and cognitive indications.
Reported research dosage
Intranasal use commonly cited at 200–600 mcg daily, split across doses.
Stability
Reasonably stable; nasal sprays often contain preservative. Half-life: very short.
Field note · N-Acetyl Selank Amidate is the common extended variant sold online.
PT-141
Bremelanotide
Melanocortin receptor agonist
Target mechanism
MC4R agonist acting centrally on sexual arousal pathways rather than on vascular tissue.
Reported research dosage
Clinically 1.75 mg as needed; research protocols commonly cite 0.5–2 mg.
Stability
Stable powder; standard solution handling. Half-life: ≈2.7 hours.
Storage
Lyophilised: cool and dark. Reconstituted: 2–8 °C, ~4 weeks.
Field note · Nausea and transient blood-pressure elevation are dose-related and common. An approved product exists.
Melanotan II
MT-2
Melanocortin receptor agonist
Target mechanism
Non-selective melanocortin agonist stimulating melanogenesis, with MC4R side effects on appetite and arousal.
Reported research dosage
Reported loading at 250–500 mcg daily, then reduced maintenance frequency.
Stability
Stable powder. Half-life: ≈33 hours.
Storage
Lyophilised: freezer. Reconstituted: 2–8 °C, protect from light.
Field note · Non-selective melanocortin stimulation is associated with darkening and change of existing moles. Dermatology monitoring is repeatedly flagged in the literature.
Epitalon
Epithalon · AEDG tetrapeptide
Pineal tetrapeptide
Target mechanism
Studied for telomerase activation and pineal regulation; almost all supporting work originates from a single Russian research group.
Reported research dosage
Reported research use at 5–10 mg daily across short 10–20 day courses, once or twice yearly.
Stability
Stable as powder. Half-life: very short.
Storage
Lyophilised: freezer. Reconstituted: 2–8 °C, ~3 weeks.
Field note · Evidence base is thin and largely un-replicated outside its originating institution.
Thymosin Alpha-1
Tα1 · Zadaxin
Immunomodulatory peptide
Target mechanism
Modulates T-cell maturation and dendritic cell function; approved in several countries as an adjunct in hepatitis and immune indications.
Reported research dosage
Clinically 1.6 mg twice weekly by subcutaneous injection.
Stability
Stable powder; solution use within weeks. Half-life: ≈2 hours.
Storage
Lyophilised: refrigerated. Reconstituted: 2–8 °C, ~2–3 weeks.
Field note · One of the better-evidenced peptides in this category, with approved products in parts of Asia and Europe.
KPV
Lysine-proline-valine · α-MSH(11-13)
Anti-inflammatory tripeptide
Target mechanism
α-MSH fragment that suppresses NF-κB signalling; studied for gut and skin inflammation, orally and topically.
Reported research dosage
Reported at 200–500 mcg daily, oral, topical or subcutaneous depending on target.
Stability
Robust small peptide. Half-life: short.
Storage
Lyophilised: cool and dark. Reconstituted: 2–8 °C, ~4 weeks.
Field note · Frequently combined with BPC-157 in reported gut protocols.
AOD-9604
hGH fragment 176-191
Growth hormone fragment
Target mechanism
C-terminal hGH fragment studied for lipolytic activity without the glycaemic effects of full-length GH.
Reported research dosage
Reported at 250–500 mcg daily, typically fasted.
Stability
Stable powder. Half-life: short.
Storage
Lyophilised: freezer. Reconstituted: 2–8 °C, ~4 weeks.
Field note · Human trials did not reproduce the fat-loss effect seen in animal models. Marketing routinely overstates the data.
Tesofensine
NS2330
Triple monoamine reuptake inhibitor (non-peptide)
Target mechanism
Inhibits noradrenaline, dopamine and serotonin reuptake, suppressing appetite centrally.
Reported research dosage
Trials used 0.25–1 mg daily, oral.
Stability
Small molecule — room-temperature stable. Half-life: ≈8 days.
Storage
Cool, dry, dark.
Field note · Cardiovascular effects — raised heart rate and blood pressure — are the documented reason development stalled.
5-Amino-1MQ
NNMT inhibitor
Small molecule (non-peptide)
Target mechanism
Inhibits nicotinamide N-methyltransferase in adipose tissue, studied for metabolic and adipocyte effects.
Reported research dosage
Commonly cited at 50–150 mg daily, oral capsule.
Stability
Room-temperature stable. Half-life: not well characterised in humans.
Storage
Cool, dry, dark.
Field note · Preclinical data only. Sold in capsule form alongside injectable peptide lines.
NAD+
Nicotinamide adenine dinucleotide
Coenzyme
Target mechanism
Central redox coenzyme and substrate for sirtuins and PARPs; administered to raise systemic availability.
Reported research dosage
Reported subcutaneous use at 50–100 mg; IV protocols run far higher over hours.
Stability
Degrades in solution; light- and heat-sensitive. Half-life: short.
Storage
Lyophilised: freezer. Reconstituted: 2–8 °C, protect from light, use promptly.
Field note · Injection-site discomfort and a flushing/pressure sensation with rapid administration are consistently reported.
Glutathione
GSH · reduced glutathione
Tripeptide antioxidant
Target mechanism
Primary intracellular antioxidant and phase-II detoxification substrate.
Reported research dosage
Reported at 100–600 mg per administration, subcutaneous or IV.
Stability
Oxidises readily once in solution. Half-life: short.
Storage
Lyophilised: cool and dark. Reconstituted: 2–8 °C, short window.
Field note · Oral bioavailability is poor, which is why injectable forms dominate this market.
GLOW blend
GHK-Cu + BPC-157 + TB-500 pre-mixed vial
Vendor blend · healing / skin stack
Target mechanism
Combines copper tripeptide-1 (collagen and remodelling signalling) with BPC-157 and TB-500 (angiogenesis and actin-mediated cell migration). No published research exists on the combination itself; the rationale is extrapolated from the components.
Reported research dosage
Common vendor formats: GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg per vial. Reported protocols reconstitute so a single draw delivers roughly 1–2 mg GHK-Cu, 200–500 mcg BPC-157 and 200–500 mcg TB-500.
Stability
GHK-Cu is the weakest link: the reconstituted blend is photosensitive and should be kept dark and cold. A deep blue tint in solution is expected from the copper. Half-life: determined by the components — bpc-157 is minutes-to-hours, tb-500 days.
Storage
Lyophilised: freezer, protected from light. Reconstituted: 2–8 °C, dark, use within ~3 weeks.
Field note · Ratios are fixed by the vendor, so you cannot titrate components independently. Blends are harder to verify by assay — confirm the lab can resolve and quantify all three compounds before paying for a test.
KLOW blend
GHK-Cu + BPC-157 + TB-500 + KPV pre-mixed vial
Vendor blend · healing / gut-inflammation stack
Target mechanism
The GLOW trio plus KPV, an α-MSH fragment studied for suppression of NF-κB–driven inflammation in gut and skin tissue. As with GLOW, no studies exist on the four-compound combination — vendor marketing outruns the literature.
Reported research dosage
Common vendor formats: GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg / KPV 10 mg per vial. Reported protocols draw to roughly 1–2 mg GHK-Cu with 200–500 mcg of each remaining component per administration.
Stability
Same photosensitive copper constraint as GLOW. Four compounds in solution increases the chance of visible aggregation — discard if cloudy or discoloured. Half-life: mixed — kpv and bpc-157 are short-acting, tb-500 multi-day.
Storage
Lyophilised: freezer, protected from light. Reconstituted: 2–8 °C, dark, use within ~3 weeks.
Field note · Marketed primarily for gut and inflammatory protocols. The four-way ratio is locked at manufacture, and identity-plus-quantity assays on quad blends are expensive and frequently inconclusive — buy from suppliers with per-batch testing or test the blend yourself.
Tirzepatide/Retatrutide blends
Vendor 'stacks' and pre-mixed vials
Combination products
Target mechanism
Two or more active compounds lyophilised into a single vial, marketed as a convenience product.
Reported research dosage
No standardised ratios exist; every vendor mixes differently.
Stability
Worst-case of the components involved. Half-life: determined by the longest-acting component.
Storage
Follow the least stable component's requirements.
Field note · Blends make independent verification substantially harder and make it impossible to attribute an effect or a problem to a single compound. Assay results on blends are frequently ambiguous.
Every compound listed is a research chemical without consumer medical approval. This page documents what the literature and market report; it is not medical advice and not a recommendation to use anything described here.